ArticleThe oncologist2019
Characteristics of
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Survival Outcomes of Patients with BRAF V600E-Mutant Resectable Extrahepatic Colorectal Oligometastases After Upfront Metastasectomy.Journal of gastrointestinal cancer · 2025Article
- Article
- Article
- Development and validation of a clinical prognostic model for BRAF V600E-mutated colorectal cancer patients based on pathological stage, microsatellite status, and primary tumor site.Frontiers in oncology · 2024Article
- Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Journal of cancer research and clinical oncology · 2023Review
- Prognostic value of Lynch syndrome, BRAFCancer medicine · 2023Article
- Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.World journal of surgical oncology · 2022Article
- BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.Journal of the National Cancer Institute · 2021Article
- The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis.Biomolecules · 2021Article
- Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies.Cancers · 2021Review
- Review
- Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?Annals of translational medicine · 2019Article
- Clinicopathological Features and Prognosis of Unresectable Colorectal Cancer With theCancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMATERIALS AND
methodsWe built a multicenter clinico-biological database gathering data from patients with
resultsWe included 287 patients (median age, 67 years [28-95]; female, 57%). Their median overall survival was 20.8 months (95% confidence interval [CI], 17.97-27.04), and median progression-free survival in the first-line setting was 4.34 months (95% CI, 3.81-5.03). Chemotherapy regimen and biological agents (antiangiogenic or anti-epidermal growth factor receptor) were not associated with overall and progression-free survival. Stage IV disease (synchronous metastases) and absence of curative-intent surgery were statistically associated with poor overall survival. Among the 194 patients with mismatch repair (MMR) status available, overall survival was significantly longer in patients with deficient MMR tumors compared with those with proficient MMR tumors (adjusted hazard ratio = 0.56;
conclusionDespite that IMPLICATIONS FOR PRACTICE: Mismatch repair (MMR) testing and resectability discussion in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.